Tofacitinib for refractory chilblain lupus erythematosus.

Elman, Scott A; Mazori, Daniel R; Merola, Joseph F

Elman, Scott A; Mazori, Daniel R; Merola, Joseph F.

Affiliation

Elman SA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Mazori DR; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.
Merola JF; Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA.

Int J Dermatol ; 61(4): e156-e157, 2022 Apr.

Article in En | MEDLINE | ID: mdl-34075576

Subject(s)

Chilblains; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Chilblains/diagnosis; Chilblains/drug therapy; Humans; Lupus Erythematosus, Cutaneous/diagnosis; Lupus Erythematosus, Cutaneous/drug therapy; Piperidines; Pyrimidines/therapeutic use

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lupus Erythematosus, Cutaneous / Chilblains / Lupus Erythematosus, Systemic Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Int J Dermatol Year: 2022 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google